piw
25 Oct 2019
Video: Instem (INS) investor presentation Here’s the Instem investor presentation by Phil Reason, CEO, given at the piworld-Progressive Equity Research event in September. Phil was over for the H1 19 results, (normally he’s in the US). A very comprehensive overview of the different parts of the business, and a positive outlook. piworld.co.uk Instem (INS) presentation at piworld – Progressive Equity Research event... Phil Reason, CEO, gives a comprehensive overview of the investment case for Instem. Introduction by Gareth Evans, Progressive Equity Research - 00:18 Phil Reason
II Editor
26 Mar 2018
NEW ARTICLE: Here's why Instem just surged by 20% "It's been a rollercoaster ride for LSE:INS:Instem since it floated on AIM in 2010, but lessons have been learned and the business is in good shape following a restructuring last year. Current forecasts are potentially conservative, too, and there ..."[link]
Carefully Does It
19 Dec 2017
Re: Artemis Aim VCT (Financial Report 30/9/1... They have been active in Japan recently.Patience certainly needed.
Red Ninja
19 Dec 2017
Artemis Aim VCT (Financial Report 30/9/17) Artemis Aim VCT (Annual Financial Report for the year ended 30 September 2017) :- Instem plc too has had a rocky twelve months. The Food and Drug Administration ("FDA"
in the US has in recent years mandated the adoption of electronic regulatory submissions and Instem, as experts in the field, look well placed to benefit. The market however is still embryonic and in the meantime the more established early stage clinical business has seen trading deteriorate. We are confident that in time trading will improve but patience will be requir
II Editor
19 Sep 2016
NEW ARTICLE: Instem worth 24% more "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth £22 million and demand for its software, which helps drug companies develop commercial drugs more efficiently, was picking up. I didn't write up the call for some ..."[link]
